{
    "organizations": [],
    "uuid": "f635ce6fc751860e807b7d047a8a9ce030dc7227",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tenax-therapeutics-announces-resul/brief-tenax-therapeutics-announces-results-of-pre-ind-meeting-with-fda-for-phase-2-study-of-levosimendan-idUSFWN1RH05B",
    "ord_in_thread": 0,
    "title": "BRIEF-Tenax Therapeutics Announces Results Of Pre-Ind Meeting With FDA For Phase 2 Study Of Levosimendan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Tenax Therapeutics Inc:\n* TENAX THERAPEUTICS ANNOUNCES RESULTS OF PRE-IND MEETING WITH FDA FOR PHASE 2 STUDY OF LEVOSIMENDAN IN PH HFPEF PATIENTS\n* FDA AGREED THAT NEW PHASE 2 CLINICAL PROTOCOL CAN BE SUBMITTED UNDER EXISTING IND\n* HFPEF PATIENTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-04-04T20:07:00.000+03:00",
    "crawled": "2018-04-05T17:25:56.024+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "tenax",
        "therapeutic",
        "inc",
        "tenax",
        "therapeutic",
        "announces",
        "result",
        "meeting",
        "fda",
        "phase",
        "study",
        "levosimendan",
        "ph",
        "hfpef",
        "patient",
        "fda",
        "agreed",
        "new",
        "phase",
        "clinical",
        "protocol",
        "submitted",
        "existing",
        "ind",
        "hfpef",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}